Investor/Media Information

Press Releases

Keyword Search
 
2017 | 2016 | 2015

March 13, 2017: Abeona Therapeutics to Present at Multiple Upcoming Investor Conferences

March 8, 2017: Abeona Therapeutics Receives Orphan Drug Designation in the European Union for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa

March 7, 2017: Abeona Therapeutics To Present At The Cowen and Company 37th Annual Health Care Conference

March 3, 2017: Abeona Therapeutics to Present at Maxim Group LLC Biotech Investor & Partnering Conference in Shanghai

February 23, 2017: Abeona Therapeutics Announces Dismissal of Securities Class Action Lawsuit

February 21, 2017: Abeona Therapeutics to Present at the 2017 RBC Capital Markets Global Healthcare Conference and 3rd Annual CRISPR Congress

February 17, 2017: Abeona Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial at the 13th Annual WORLDSymposium™ 2017

February 7, 2017: Abeona Therapeutics Announces Presentations and Posters at the 13th Annual WORLDSymposium™ 2017

February 1, 2017: Abeona Therapeutics Enrolls First High Dose Subject in Ongoing Phase 1/2 Gene Therapy Clinical Trial in Sanfilippo Syndrome Type A

January 19, 2017: Abeona Therapeutics Receives Orphan Drug Designation in The European Union for ABO-101 Gene Therapy in Sanfilippo Syndrome Type B

January 17, 2017: Abeona Therapeutics to Present at Phacilitate Cell & Gene Therapy World 2017

January 3, 2017: Abeona Therapeutics Receives Orphan Drug Designation in The European Union for ABO-201 Gene Therapy Program in Juvenile Batten Disease

December 6, 2016: Abeona Therapeutics to Present at 2016 Genetic Rx Boston Biotech Conference at Harvard Medical School

November 15, 2016: Abeona Therapeutics to Present at World Orphan and Drug Congress Europe 2016

November 10, 2016: Abeona Therapeutics Announces Third Quarter 2016 Financial Results and Recent Clinical Highlights

November 5, 2016: Abeona Therapeutics Honored with Partner in Progress Award from DEBRA of America

November 3, 2016: Abeona Therapeutics to Present at Alliance of Regenerative Medicine 4th Annual Advanced Therapies Investor Day in London, UK

November 2, 2016: Abeona Therapeutics Announces JAMA Publication of Positive Phase 1 Study Results for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa

November 1, 2016: Abeona Therapeutics Inc. Announces Closing of its Underwritten Offering of Common Stock

October 27, 2016: Abeona Therapeutics Announces Pricing of Public Offering of Common Stock

October 26, 2016: Abeona Therapeutics Announces Public Offering of Common Stock

October 25, 2016: Abeona Therapeutics Announces Fast Track Designation from FDA for ABO-102 in Sanfilippo Syndrome Type A

October 20, 2016: Abeona Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial at Orphan Drugs & Rare Disease Conference, London UK

October 18, 2016: Abeona Therapeutics Receives Orphan Drug Designation in The European Union for ABO-102 Gene Therapy in Sanfilippo Syndrome Type A

October 14, 2016: Abeona Therapeutics to Present Top-Line Data of Low-Dose Cohort for ABO-102 in Phase 1/2 Clinical Trial for MPS IIIA Patients at Upcoming Orphan Drugs and Rare Disease Congress October 19-20th in London, UK

October 7, 2016: Abeona Therapeutics Announces Publication of Preclinical Data Supporting Clinical Translation of Juvenile Batten Disease Gene Therapy

October 5, 2016: Abeona Therapeutics Announces Data Safety Monitoring Board Approves ABO-102 Dose Escalation for Second Cohort in Phase 1/2 Clinical Trial for Sanfilippo Syndrome Type A

October 4, 2016: Abeona Therapeutics to Present at Jefferies Gene Editing & Gene Therapy Summit

September 29, 2016: Abeona Therapeutics to Present at Cell Gene Meeting on the Mesa

September 26, 2016: Abeona Therapeutics Enrolls First Patient in Phase 2 for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa

September 23, 2016: Abeona Therapeutics to Present at Ladenburg Thalmann 2016 Healthcare Conference

September 21, 2016: Abeona Therapeutics Announces Licensing of the AIM(TM) Next Generation AAV Gene Therapy Vector Platform From The University of North Carolina at Chapel Hill

September 16, 2016: Abeona Therapeutics to Present at 2016 Aegis Growth Conference

September 15, 2016: Abeona Therapeutics Announces Publication of Preclinical Data Supporting Clinical Translation of MPS IIIA Gene Therapy

September 8, 2016: Abeona Therapeutics Enrolls 5th Patient in Phase 1/2 Gene Therapy Clinical Trial for Epidermolysis Bullosa

September 7, 2016: Abeona Therapeutics to Present at Rodman & Renshaw 18th Annual Global Investment Conference

September 1, 2016: Abeona Therapeutics to Present at Landmark Angels 6th Annual Investing for Cures 2016 Conference

August 29, 2016: Abeona Therapeutics Completes Enrollment of Low-Dose Cohort for ABO-102 in Phase 1/2 Clinical Trial for MPS IIIA Patients

August 16, 2016: Abeona Therapeutics Announces Second Quarter 2016 Financial Results and Recent Clinical Highlights

August 9, 2016: Abeona Therapeutics, EB Research Partnership and EB Medical Research Foundation to Collaborate on Epidermolysis Bullosa (EB) Treatments

August 4, 2016: Abeona Therapeutics Announces European Regulatory Approval for Phase 1/2 Gene Therapy Clinical Study for Patients With Sanfilippo Syndrome Type A (MPS IIIA)

August 2, 2016: Abeona Therapeutics Provides Update on Initial Subjects in Sanfilippo Type A Gene Therapy Trial, Demonstrating Encouraging Early Biopotency Signals

June 30, 2016: Abeona Therapeutics to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference

June 7, 2016: Abeona Therapeutics to Present at Jefferies 2016 Global Healthcare Conference

June 2, 2016: Abeona Therapeutics to Present at 2016 BIO International Convention

May 24, 2016: Abeona Therapeutics Announces FDA Allowance of Investigational New Drug (IND) for Phase 1/2 Clinical Study With ABO-101 Gene Therapy for Patients With Sanfilippo Syndrome Type B (MPS IIIB)

May 23, 2016: Abeona Therapeutics to Present at UBS 2016 Global Healthcare Conference

May 17, 2016: Abeona Therapeutics Doses First Patient in Phase 1/2 Trial With ABO-102 Gene Therapy for Patients With Sanfilippo Syndrome Type A (MPS IIIA)

May 16, 2016: Abeona Therapeutics Announces First Quarter 2016 Summary Financial Results and Recent Operational Highlights

May 3, 2016: Abeona Therapeutics Appoints Christine Silverstein as Vice President of Investor Relations

April 15, 2016: Abeona Therapeutics to Present at Gene, Cell and Molecular Therapies for Inherited Metabolic Diseases Meeting

March 21, 2016: Abeona Therapeutics to Present at Alliance of Regenerative Medicine's (ARM) 4th Annual Cell & Gene Therapy Investor Day

March 10, 2016: Abeona Therapeutics to Present at the 28th Annual ROTH Conference

March 8, 2016: Abeona Therapeutics Announces Fourth Quarter and Full Year 2015 Summary Financial Results and Recent Operational Highlights

March 2, 2016: Abeona Therapeutics Highlights New Preclinical Juvenile Neuronal Ceroid Lipofuscinosis (JNCL) Data at WORLDSymposium(TM) 2016

February 29, 2016: Abeona Therapeutics Announces FDA Allowance of Investigational New Drug (IND) for Systemic AAV Phase 1/2 Clinical Study With ABO-102 Gene Therapy for Patients With Sanfilippo Syndrome Type A (MPS IIIA)

February 24, 2016: Abeona Therapeutics, Inc. to Present on CRISPR/CAS9 Technology Platform Progress at CRISPR Precision Gene Editing Congress

February 9, 2016: Abeona Therapeutics to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference

February 4, 2016: Abeona Therapeutics to Present at the 18th Annual BIO CEO & Investor Conference

January 11, 2016: Abeona Therapeutics Announces Initial European Regulatory Approvals for Phase 1/2 Gene Therapy Clinical Studies for Patients With Sanfilippo Syndromes Type A (MPS IIIA) and Type B (MPS IIIB)

December 1, 2015: Abeona Therapeutics to Present at Piper Jaffray 27th Annual Healthcare Conference

November 18, 2015: Abeona Therapeutics to Present at Jefferies 2015 Global Healthcare Conference

November 17, 2015: Abeona Therapeutics Reports Financial Results and Highlights for Third Quarter 2015

October 6, 2015: Abeona Therapeutics Announces License for Next Generation AAV Delivery Vector for Fanconi Anemia and Rare Blood Disease Platform

October 1, 2015: Abeona Therapeutics to Present at 2015 Stem Cell Meeting on the Mesa

September 3, 2015: Abeona Therapeutics to Present at 2015 Rodman & Renshaw Annual Global Investment Conference

August 24, 2015: Abeona Therapeutics to Present at the 2015 Sidoti Emerging Growth Conference

August 17, 2015: Abeona Therapeutics Announces Recent Highlights and Second Quarter 2015 Conference Call

August 3, 2015: Abeona Therapeutics Announces Closing of Upsized $15.5 Million Equity Financing With Institutional Investors and Management

July 28, 2015: Abeona Therapeutics Announces $8.5 Million Equity Financing With Current Institutional Investors and Directors

July 7, 2015: Abeona Therapeutics Provides Update on SDF(TM) (Salt Diafiltration) Plasma Fractionation Products

July 1, 2015: Abeona Therapeutics Raises Additional $4.6 Million Through Warrant Exercises in Q2 15

June 22, 2015: Abeona Therapeutics Set to Join Russell Global, Russell 3000(R) and Russell MicroCap(R) Indexes

June 19, 2015: PlasmaTech Biopharmaceuticals Announces Name Change to Abeona Therapeutics to Reflect Broader Rare Disease Commitment

June 17, 2015: PlasmaTech Biopharmaceuticals to Present at the 2015 BIO International Convention

June 15, 2015: PlasmaTech Biopharmaceuticals Expands Rare Disease Pipeline With License Agreement for Gene Therapy in Fanconi Anemia & CRISPR/Cas9-Based Technology Platform for Rare Blood Disorders

June 8, 2015: PlasmaTech Biopharmaceuticals Announces License Agreement for AAV Gene Therapy to Treat Patients With Juvenile Batten Disease

June 1, 2015: PlasmaTech Biopharmaceuticals to Present at the 2015 Jefferies Healthcare Conference

May 29, 2015: PlasmaTech Biopharmaceuticals to Present at the 2015 LD Micro Invitational Conference

May 27, 2015: PlasmaTech Biopharmaceuticals to Present at the 2015 Marcum MicroCap Conference

May 26, 2015: REMINDER: PlasmaTech Biopharmaceuticals First Quarter 2015 Conference Call Tomorrow

May 20, 2015: PlasmaTech Biopharmaceuticals Announces Orphan Drug and Rare Pediatric Disease Designations From FDA

May 18, 2015: PlasmaTech Biopharmaceuticals Closes Abeona Therapeutics Acquisition

May 15, 2015: PlasmaTech Biopharmaceuticals Files First Quarter 2015 Financial Results and Announces Conference Call to Provide Business Update

May 14, 2015: PlasmaTech Biopharmaceuticals Announces Completion of Sanfilippo Syndrome (MPS IIIB) Toxicology Studies at American Society of Gene and Cell Therapy Annual Meeting

May 12, 2015: PlasmaTech Biopharmaceuticals Announces Appointment of Todd Wider, MD to Board of Directors

May 11, 2015: PlasmaTech Biopharmaceuticals Closes $10 Million Financing

May 6, 2015: PlasmaTech Biopharmaceuticals Announces Agreement to Acquire Abeona Therapeutics LLC

April 29, 2015: Understanding Radiation Proctitis: New Approach Addresses the Needs of Ovarian, Colon and Prostate Cancer Patients

April 24, 2015: PlasmaTech Biopharmaceuticals Announces Closing of Upsized $7 Million Private Placement

April 15, 2015: New Breakthroughs to Avoid Shortage of Treatment for Those With Inherited COPD

April 14, 2015: PlasmaTech Biopharmaceuticals Bolsters Scientific Advisory Board With Alpha-1 Expert Charlie Strange, M.D.

April 7, 2015: PlasmaTech Biopharmaceuticals Appoints Alpha-1 Expert Robert Sandhaus, MD, Ph.D. To Its Scientific Advisory Board

April 2, 2015: PlasmaTech Biopharmaceuticals' Announces $5 million private placement

April 1, 2015: PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements

March 31, 2015: PlasmaTech Biopharmaceuticals' Partner Hanmi Pharmaceuticals Receives Marketing Approval For MuGard In Korea

March 10, 2015: PlasmaTech Biopharmaceuticals To Present at 27th Annual ROTH Capital Partners Conference - NEW TIME SLOT

March 5, 2015: PlasmaTech Biopharmaceuticals' Announces Initiation Of Enrollment Of MuGard® Trial For Afinitor® (Everolimus; Novartis) - Related Stomatitis At UCLA Breast Cancer Center

March 3, 2015: PlasmaTech Biopharmaceuticals To Present at 27th Annual ROTH Capital Partners Conference

February 9, 2015: PLASMATECH BIOPHARMACEUTICALS INC Files SEC form 8-K, Other Events

February 6, 2015: PlasmaTech Biopharmaceuticals To Present at 17th Annual BIO CEO & Investor Conference

January 14, 2015: PlasmaTech Biopharmaceuticals to Present at Biotech Showcase 2015

January 12, 2015: PlasmaTech Biopharmaceuticals To Present at OneMedForum Investor Conference in San Francisco

January 6, 2015: PLASMATECH BIOPHARMACEUTICALS INC Files SEC form 8-K, Other Events

January 5, 2015: PLASMATECH BIOPHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articl

December 24, 2014: PLASMATECH BIOPHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits

December 19, 2014: PLASMATECH BIOPHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits

December 18, 2014: PlasmaTech Biopharmaceuticals, Inc. Announces Pricing of $14,000,000 Public Offering and Listing on NASDAQ

December 5, 2014: PLASMATECH BIOPHARMACEUTICALS INC Files SEC form 8-K, Other Events

December 3, 2014: PLASMATECH BIOPHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statement

November 14, 2014: PLASMATECH BIOPHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report

Press Releases

Stay up to date with the latest news from Abeona Therapeutics.
Read Press Releases »

Events & Presentations

Watch past webcasts, listen to conference calls, and view a schedule of events.
View Materials »

Stock Information

Everything you need to know about Abeona’s stock history and analysis.
View Stock Information »

Financial Information

View all of Abeona’s SEC filings, quarterly reports, and other pertinent documents.
View Financial Information »

Corporate Governance

Learn about Abeona’s Board of Directors, Code of Ethics, and Governing Guidelines.
Learn More »

Contact Information

Get in touch about investments and business collaborations.
Contact Us »